aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-11-04 16:49Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against ATyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $10,000 in ATyr between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against ATyr Pharma, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against ATyr Pharma - The complaint alleges that ATyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [6]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - Following the release of the study results, ATyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].